Poseida Therapeutics, Inc. is built on technology platforms that it says can deliver safer and more effective cell and gene therapies, but the company saw its stock sink 30.3% to close at $9.06 on 18 August after revealing that the Phase I clinical trial for its chimeric antigen receptor T-cell (CAR-T) therapy P-PSMA-101 was put on a clinical hold following a metastatic castrate-resistant prostate cancer (mCRPC) patient’s death from liver failure.
San Diego-based Poseida said in a US Securities and Exchange Commission (SEC) filing after the stock market closed on 17...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)